Atra Zist Aray Knowledge-Based Company (public joint stock), listed under the symbol “DATRA,” announced in an official statement that all production lines remain fully operational and that the manufacturing and supply of its specialized therapeutic and cosmetic products continue without any interruption.

According to the company’s Public Relations Department, despite recent nationwide challenges and the damage inflicted on certain infrastructure sectors, Atra Zist Aray’s production activities have not ceased since the onset of the war. All production units—including manufacturing, quality control, and product distribution—have remained consistently active. As stated in the report, the company’s therapeutic and cosmetic products continue to be delivered to medical centers, dermatology and aesthetic clinics, and end‑users without any disruption in availability.

The statement further emphasizes:

“Given the critical importance of uninterrupted patient access to therapeutic and skincare products, the company has implemented several strategic measures in recent months to strengthen the resilience of its supply chain. Increasing reserves of essential raw materials, expanding production line capacities, and reinforcing collaborations with pharmaceutical and clinical distribution networks have ensured that—even under challenging wartime conditions—production and supply have continued without halt.”

Atra Zist Aray is recognized as one of the leading producers of knowledge‑based, biotechnology‑driven medical aesthetic and skincare products in the country. Owing to its advanced and deeply institutionalized expertise in pharmaceutical biotechnology, the company currently undertakes contract manufacturing for numerous prominent beauty brands nationwide.

Leveraging its strong technical capabilities and specialized R&D biotechnology laboratories, Atra Zist Aray also plans to expand into therapeutic biotechnology-based pharmaceuticals in the near future.